framycetin has been researched along with Adenomatous Polyposis Coli, Familial in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ajami, NJ; Auchtung, TA; Banerjee, S; Berger, FG; Carson, JA; Chakraborty, P; Chanda, A; Chatzistamou, I; Chumanevich, A; Debnath, I; Depaep, S; Fayad, R; Gummadidala, PM; Kaur, K; O'Brien, JL; Omebeyinje, MH; Petrosino, JF; Saxena, A; Sougiannis, AJ | 1 |
| Alexander, DP; Becker, JM | 1 |
1 trial(s) available for framycetin and Adenomatous Polyposis Coli, Familial
| Article | Year |
|---|---|
Colectomy, mucosal proctectomy, and ileal pouch-anal anastomosis. A prospective trial of optimal antibiotic management.
Topics: Adenomatous Polyposis Coli; Administration, Oral; Adult; Anal Canal; Anastomosis, Surgical; Cefoxitin; Colectomy; Colitis, Ulcerative; Double-Blind Method; Drug Therapy, Combination; Erythromycin; Female; Gardner Syndrome; Humans; Ileum; Infection Control; Infusions, Intravenous; Male; Neomycin; Postoperative Care; Postoperative Complications; Premedication; Prospective Studies; Rectum | 1991 |
1 other study(ies) available for framycetin and Adenomatous Polyposis Coli, Familial
| Article | Year |
|---|---|
Antibiotic-mediated bacteriome depletion in Apc
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anti-Bacterial Agents; Colon; Disease Models, Animal; Disease Progression; Gastrointestinal Microbiome; Goblet Cells; Intestinal Mucosa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neomycin; Streptomycin; Vancomycin | 2018 |